CytoMed (GDTC) Files Form 144 for 54,644 Shares on NASDAQ

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• Disclosure completeness: Acquisition details, recent sales, and intended sale amount are reported, meeting Rule 144 disclosure requirements
• Proposed sale size is small: 54,644 shares is ~0.47% of 11,733,712 outstanding shares, limiting potential market impact

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Form 144 disclosing proposed sale of a small percentage of outstanding shares after prior open-market sales.

The filing is procedural and provides transparency about an intended disposal of equity by a holder that acquired shares by subscription in 2021. The 54,644-share sale represents approximately 0.47% of the issuer's reported outstanding shares (11,733,712), which is small in absolute and relative terms and is unlikely to materially affect company capitalization. The report of 26,838 shares sold across August–September 2025 documents recent liquidity events from the same account; reported gross proceeds per trade are shown but are modest in size. From a market-impact perspective this is a routine disclosure fulfilling Rule 144 requirements.

Compliance / Corporate Governance Expert

TL;DR: The filing appears complete for Rule 144 notice purposes and includes acquisition and recent sale history required by the rule.

The form supplies the acquisition date, nature of acquisition (share subscription), payment method (cash), and a detailed list of recent dispositions with dates and gross proceeds, meeting typical disclosure expectations. The filer also includes the required certification about material nonpublic information. There is no disclosure of a 10b5-1 trading plan or other instructions within the form text provided. For compliance assessment, this filing is a standard seller notice without apparent omissions in the information fields shown.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Bank of Singapore 63 Market St, #22-00 Singapore U0 049842	54644	102731.00	11733712	09/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	04/22/2021	Share Subscription	Issuer			711822	04/20/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/01/2025	134	256.96
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/07/2025	12	22.41
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/08/2025	238	444.50
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/11/2025	76	138.15
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/12/2025	980	1764.94
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/13/2025	500	888.89
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/15/2025	81	145.62
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/18/2025	324	582.37
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/19/2025	583	1038.80
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/21/2025	498	885.19
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/22/2025	1358	2464.14
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	08/25/2025	4166	8292.36
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/09/2025	1656	3114.09
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/10/2025	3243	6366.95
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/11/2025	2279	4603.68
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/12/2025	4650	9911.15
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/15/2025	745	1646.01
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/17/2025	2850	5397.46
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/18/2025	1865	3569.18
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	09/19/2025	600	1131.39

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by GDTC disclose?

The filer intends to sell 54,644 ordinary shares (~$102,731 aggregate market value) on or about 09/23/2025 on NASDAQ.

When and how were the shares being offered for sale originally acquired?

The shares were acquired by share subscription on 04/22/2021, with payment recorded as cash (payment date listed as 04/20/2021).

How many shares has this account sold recently according to the filing?

The filing lists 19 separate sales from Aug–Sep 2025 totaling 26,838 shares with gross proceeds reported per transaction.

What percentage of GDTC’s outstanding stock does the proposed sale represent?

Approximately 0.47% (54,644 of 11,733,712 shares outstanding as reported in the filing).

Does the filing indicate any undisclosed material information about the company?

No. The signer represents they do not know any material adverse information not publicly disclosed.